China's Fosun in $1.3 billion deal to buy 86% stake in Gland Pharma

28 July 2016

China’s Fosun Pharma (HK: 02196) has agreed to buy an 86% stake in Gland Pharma, an Indian injectables company backed by American investment company KKR, for a sum of up to $1.3 billion.

The Shanghai based company plans to raise up to $800 million in loans to help fund the deal, while KKR, which invested in Gland two years ago, is selling its stake.

Hyderabad-based Gland is a global supplier of a variety of medicines administered through vials, syringes, bags and pumps. Its largest exports market is the USA, where sales of injectables are predicted to grow by about 10% annually in the next five years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK